Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Targeted oncology

• Publication date

  2014-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11523-013-0283-8PMID 23821376
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.

  2014cited by this paper
• Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.

  2012cited by this paper
• Contrasting treatment‐specific survival using double‐robust estimators

  2012cited by this paper
• PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

  2012cited by this paper
• Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

  2011cited by this paper
• Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

  2011cited by this paper
• TP53 mutations in irinotecan-refractory KRAS wt-BRAF wt metastatic colorectal cancer patients treated with cetuximab-based chemotherapy.

  2011cited by this paper
• Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

  2011cited by this paper
• Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

  2011cited by this paper
• BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

  2011cited by this paper
• Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

  2011cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa

  2010cited by this paper
• TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

  2009cited by this paper
• TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

  2009cited by this paper
• PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

  2007cited by this paper
• KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand.

  2006cited by this paper
• Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis

  2005cited by this paper
• P53 abnormalities and outcomes in colorectal cancer: a systematic review

  2005cited by this paper
• Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.

  2004cited by this paper
• New options and old dilemmas in the treatment of patients with advanced colorectal cancer.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

  2003cited by this paper
• Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

  2002cited by this paper
• Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas

  1996cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Long-term stable disease with mFOLFOX6 chemotherapy plus cetuximab for bone marrow metastasis from rectal cancer: A case report

  2023cites this paper
• The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy

  2021influential citation
• Frequency of NRAS gene mutations among the patients with wild type KRAS colorectal cancers in Southern-Eastern Serbia

  2021cites this paper
• Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.

  2021cites this paper
• Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China

  2021cites this paper
• Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG).

  2020cites this paper
• Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

  2020cites this paper
• Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.

  2019cites this paper
• Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

  2018cites this paper
• Frequency of NRAS Gene Mutation in Wild Type KRAS and BRAF Colorectal Cancers; a Single Center Study

  2018cites this paper
• Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

  2018cites this paper
• KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis

  2017cites this paper
• KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer.

  2017cites this paper
• Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

  2017cites this paper
• Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

  2016cites this paper
• miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma

  2016cites this paper
• KRAS Mutant Status, p16 and β-catenin Expression May Predict Local Recurrence in Patients Who Underwent Transanal Endoscopic Microsurgery (TEMS) for Stage I Rectal Cancer.

  2016cites this paper
• In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity

  2016cites this paper
• Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

  2016cites this paper
• Pharmacogénétique des analogues nucléosidiques : Cytidine déaminase et issue clinique

  2015cites this paper
• Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.

  2015cites this paper
• Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS‐BRAF wild‐type colorectal cancer receiving cetuximab or panitumumab

  2015cites this paper
• The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors

  2015cites this paper
• Development of a pipeline and protocols for next generation sequencing of blood and formalin-fixed, paraffin-embedded tumour DNA samples

  2015cites this paper
• PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

  2015cites this paper
• Role of cetuximab in first-line treatment of metastatic colorectal cancer.

  2014cites this paper
• Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients

  2014cites this paper
• TP53 Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon

  2014cites this paper
• Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status

  2014cites this paper
• Characterization of the DNA methylation patterns of chemosensitive and chemoresistant human cancer cells: Biological and clinical impact

  2014cites this paper
• Impact of cetuximab in current treatment of metastatic colorectal cancer.

  2014cites this paper
• TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial.

  2014cites this paper
• Impact of cetuximab in current treatment of metastatic colorectal cancer

  2014cites this paper
• FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.

  2014cites this paper